drug delivery

Novartis signs $3.2B deal for Alteogen’s injection technology

Novartis announced Wednesday it has signed a licensing and option agreement with South Korean biotech Alteogen worth up to $3.22 billion, gaining access to technology that converts intravenous drugs into simpler under-the-skin injections.